Nuvation Bio (NUVB)
(Delayed Data from NYSE)
$3.22 USD
+0.02 (0.63%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $3.21 -0.01 (-0.31%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth F Momentum F VGM
Income Statements
Fiscal Year end for Nuvation Bio Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | NA |
Cost Of Goods | 0 | 0 | 0 | 0 | NA |
Gross Profit | 0 | 0 | 0 | 0 | NA |
Selling & Adminstrative & Depr. & Amort Expenses | 100 | 120 | 93 | 3 | 0 |
Income After Depreciation & Amortization | -100 | -120 | -93 | -3 | 0 |
Non-Operating Income | 24 | 16 | 6 | 0 | NA |
Interest Expense | 0 | 0 | 0 | 0 | NA |
Pretax Income | -76 | -104 | -87 | -3 | NA |
Income Taxes | 0 | 0 | 0 | 0 | NA |
Minority Interest | 0 | 0 | 0 | 0 | NA |
Investment Gains/Losses | 0 | 0 | 0 | 0 | NA |
Other Income/Charges | 0 | 0 | 0 | 0 | NA |
Income From Cont. Operations | -76 | -104 | -87 | -3 | NA |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | NA |
Net Income (GAAP) | -76 | -104 | -87 | -3 | NA |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -100 | -120 | -93 | -3 | 0 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | NA |
Income After Depreciation & Amortization | -100 | -120 | -93 | -3 | 0 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 218.88 | 216.72 | 197.89 | 277.53 | NA |
Diluted EPS Before Non-Recurring Items | -0.35 | -0.48 | -0.44 | -0.23 | NA |
Diluted Net EPS (GAAP) | -0.35 | -0.48 | -0.44 | -0.80 | NA |
Fiscal Year end for Nuvation Bio Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 1.44 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 1.35 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.09 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 470.48 | 20.20 | 20.83 | 26.34 | 26.13 |
Income After SG&A, R&D, and Dept/Amort Expenses | -470.39 | -20.20 | -20.83 | -26.34 | -26.13 |
Non-Operating Income | 8.03 | 5.41 | 7.04 | 6.69 | 5.49 |
Interest Expense | 0.13 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -462.49 | -14.79 | -13.79 | -19.65 | -20.64 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -462.49 | -14.79 | -13.79 | -19.65 | -20.64 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -462.49 | -14.79 | -13.79 | -19.65 | -20.64 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 244.74 | 219.05 | 218.99 | 218.94 | 218.85 |
Diluted EPS Before Non-Recurring Items | -0.15 | -0.07 | -0.06 | -0.09 | -0.09 |
Diluted Net EPS (GAAP) | -1.89 | -0.07 | -0.07 | -0.09 | -0.09 |